XML 41 R11.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

INVENTORY | 12 Months Ended
--- | ---
Dec. 31, 2023
Inventory Disclosure [Abstract] |
INVENTORY | INVENTORY Inventory consisted of the following (in thousands):
| December 31,
| 2023 |  | 2022
Raw materials | $ | 2,691 |  |  | $ | — |
Work-in-process | 3,406 |  |  | — |
Finished goods | — |  |  | — |
Total inventory | $ | 6,097 |  |  | $ | — |
The Company’s capitalized inventory consists of costs incurred subsequent to FDA approval of REZZAYO in March 2023. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred. There were no inventory write downs during the year ended December 31, 2023.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration